Major advances in our understanding of cancer pathogenesis and therapy have come from
efforts to catalog genomic alterations in cancer. A growing number of large-scale genomic …

Whereas the PROTAC approach to target protein degradation greatly benefits from rational
design, the discovery of small-molecule degraders relies mostly on phenotypic screening …

Cereblon (CRBN) is a primary target of thalidomide and mediates its multiple
pharmacological activities, including teratogenic and antimyeloma activities. CRBN …

Targeted therapies for cancer are typically small molecules or monoclonal antibodies that
act by inhibiting the activity of specific proteins that drive tumor growth. Although many of …

The Wnt signaling pathway plays important roles in embryonic development, homeostatic
processes, cell differentiation, cell polarity, cell proliferation, and cell migration via the β …

Abstract WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine
methyltransferase complex, is critically involved in oncogenesis and represents an attractive …

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

The ubiquitin/proteasome system is a primary conduit for selective intracellular protein
degradation. Since its discovery over 30 years ago, this highly regulated system continues to …

Protein degradation is an emerging therapeutic strategy with a unique molecular
pharmacology that enables the disruption of all functions associated with a target. This is …

Summary The PI3K/AKT signaling cascade is one of the most commonly dysregulated
pathways in cancer, with over half of tumors exhibiting aberrant AKT activation. Although …